Clinical Trials

28 enrolled

Adenocarcinoma of Endometrium

NCT01560416 2026-03-03

Fulvestrant With or Without Ganetespib in HR+ Breast Cancer

50 enrolled 14 charts

Breast Neoplasms, Neoplasm Metastasis

NCT01602380 2026-02-27

FALCON

Phase 3 Completed

462 enrolled 20 charts

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT02860000 2026-02-27

Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer

96 enrolled 34 charts

Breast Neoplasms

NCT01597388 2026-02-24

AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer

99 enrolled 61 charts

Advanced Metastatic Breast Cancer

NCT05022342 2026-02-23

SPEAR

Completed

595 enrolled

Breast Neoplasms

NCT05101564 2026-02-12

Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer

19 enrolled 10 charts

Breast Neoplasms

NCT03781063 2026-01-28

Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

100 enrolled

Breast Neoplasms

NCT03056755 2026-01-13

BYLieve

383 enrolled 16 charts

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT03685331 2026-01-09

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

9 enrolled

Breast Neoplasms

NCT05963984 2025-12-26

SUMIT-BC

60 enrolled

Breast Neoplasms

NCT04603183 2025-12-12

ABIGAIL

162 enrolled

Breast Cancer Metastatic

NCT05631795 2025-12-03

ALPINIST

Phase 4 Completed

40 enrolled

Endocrine

Multiple Endocrine Neoplasia Type 1

NCT02630693 2025-11-25

Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

180 enrolled 14 charts

Breast Neoplasms

NCT03363893 2025-11-12

Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies

Phase 1/2 Completed

124 enrolled

Tumor-Agnostic

Neoplasms

NCT03280563 2025-11-10

MORPHEUS HR+BC

Phase 1/2 Completed

144 enrolled 25 charts

478 enrolled 16 charts 1 FDA

Breast Neoplasms

NCT03778931 2025-09-15

EMERALD

Phase 3 Completed

Breast Neoplasms

NCT02958852 2025-09-10

ABC-SE

126 enrolled

Breast Neoplasms, Neoplastic Cells, Circulating

NCT07096024 2025-08-28

A Study to Understand About the Study Medicine Palbociclib in Breast Cancer Patients After it is Out in the Japanese Market

Completed

1,772 enrolled

Breast Neoplasms

NCT04300790 2025-07-29

METALLICA

69 enrolled

BreastEndocrine

Breast Neoplasms, Hyperglycemia, Neoplasm Metastasis, Multiple Endocrine Neoplasia Type 1

NCT04352777 2025-07-20

Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer

18 enrolled

Breast Neoplasms

NCT03767335 2025-06-26

B-PRECISE-01

62 enrolled 18 charts

Breast Neoplasms

NCT03099174 2025-06-24

This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer

133 enrolled 26 charts

Breast Neoplasms, Neoplasms

NCT00253422 2025-06-04

SoFEA

Phase 3 Completed

698 enrolled 19 charts

Breast Neoplasms

NCT01441947 2025-05-25

Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer

68 enrolled 11 charts

Breast Neoplasms, Neoplasm Metastasis

NCT05054374 2025-05-23

A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer

Phase 1/2 Completed

6 enrolled 4 charts

Breast Neoplasms

NCT03554044 2025-05-21

T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer

20 enrolled